FDA Issues 2020 Report on the State of Pharmaceutical Quality

download The Office of Pharmaceutical Quality (OPQ) within FDA’s Center for Drug Evaluation and Research has published its fiscal year(FY) 2020 Report on the State of Pharmaceutical Quality. The report contains select quality indicators and trends that provide insight into the quality of the U.S. drug supply chain. The State of Pharmaceutical Quality is a summary of various measures of the pharmaceutical manufacturing industry’s ability to deliver quality drugs to U.S. patients and consumers. This FY2020 report includes an analysis of the impact of the COVID-19 public health emergency on the pharmaceutical supply chain and quality of drugs. FDA uses the State of Pharmaceutical Quality to inform regulatory decision-making and surveillance activities. This information is publicly available for external stakeholders to better understand the quality of the U.S. drug supply. Additionally, this information is used to identify better ways to engage the pharmaceutical manufacturing industry and drive industry improvements, which are essential to strengthening global pharmaceutical supply chains. A quality product of any kind consistently meets the expectations of the user. Drugs are no different. Patients expect safe and effective drugs with every dose they take. Pharmaceutical quality is achieved by assuring every dose is safe and effective – and free of contamination and defects. Quality is what gives patients and consumers confidence in their next dose of medicine. Please read OPQ’s Report on the State of Pharmaceutical Quality and join us in a commitment to quality.